The urinary complex TIMP-2*IGFBP7 proved effective in predicting the development of severe or moderate AKI in high-risk patients with significant accuracy and stability [19], and its clinical applications have rapidly increased [18] since the Food and Drug Administration (FDA) approval of the test “NephroCheck®” in patients 21 years of age or older in 2014. This evidence concerns the gene IGFBP7 and acute kidney injury.